Contact this trialFirst, we need to learn more about you.
Monoclonal Antibodies
Pembrolizumab + Bevacizumab for Brain Cancer and Lung Cancer
Recruiting1 awardPhase 2
New Haven, Connecticut
This trial is studying a new combination of drugs to treat brain metastases from melanoma or NSCLC. The trial will enroll 53 patients and will last 84 months.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.